Technology adoption fuels growth for pharma tech firm
Company has experienced double digit growth across its automation, MES and managed services offering.
Zenith Technologies has strengthened its global workforce, recruiting 100 people over the past year in response to growing demand for manufacturing execution system (MES) and automation technology in the pharma sector.
The global life science technology firm, with headquarters in Cork and 16 offices worldwide, has experienced double digit growth across its automation, MES and managed services offering, which has been supported by around a 50% increase in headcount since 2014. It’s 700 plus strong team of engineers supports some of the world’s largest pharma firms with the implementation of new technology.
As demand for technology grows in the pharma sector against a backdrop of an industry-wide engineering skills shortage, Zenith is also investing in training future talent. The company has just made a record intake of more than 30 graduates from across Ireland, the UK, the US and Singapore.
Shea Fahy, HR director at Zenith commented: “Recruiting skilled and experienced staff is important for the future of our business and the growing adoption of technology in the life sciences space also demands engineers to ensure effective implementation and support solutions. We’re proud that our one-year graduate programme addresses the engineering skills gap head on, supporting the talent of the future.”
Graduates will benefit from an initial 2-week induction and 6-week mentoring session from experienced engineers, where they will learn to identify customer challenges and select the appropriate technological solutions.
“We have worked hard to build up a reputation as a trusted technology partner in the life sciences sector. Our employees have the opportunity to work with some of the largest pharmaceutical companies in the world, with a structured approach to continued learning and development to enhance their engineering skillset.
“We are incredibly proud of the growth we have been able to achieve. We will continue to strengthen our ability to support our customers and by the end of this year, we expect to have doubled our headcount from 2014,” Fahy continued.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance